INTRODUCTION
============

The rapidly growing medical device industry is projected to be valued at 800 billion dollars by the year 2030.^[@R1]^ The label "medical device" can be applied to a wide range of products, from gauze to synthetic skin substitutes.

The Food and Drug Administration (FDA) is the professional body responsible for the regulation and safety of medical devices in the United States.^[@R2]^ They define a medical device as: "an instrument, apparatus, implement, machine, \[...\] intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease \[...\]."^[@R2]^ The FDA originally began regulating medical devices under the Medical Device Regulation Act (MDRA) in 1976 following the adverse events and deaths related to intrauterine devices, which harmed an estimated 200,000 women and their families.^[@R3]^

The MDRA was passed in 1976 to establish risk-based classifications for the evaluation of medical devices. The MDRA framework included 3 categories (Class I--III), in order of increasing potential risk (Table [1](#T1){ref-type="table"}).^[@R2]^ Low-risk devices (Class I) do not require FDA clearance before marketing (eg, tongue depressors). Moderate-risk devices (Class II) require a 501k Premarket Notification, a less rigorous pathway to market. Class III devices are considered to have the highest potential risk and undergo the most stringent requirements before being able to be marketed to the public.^[@R2]^ A high-risk device is that which "supports or sustains human life, is of substantial importance in preventing impairment of human health, or presents a potential, unreasonable risk of illness or injury."^[@R2]^ Class III devices must submit an application for review by an advisory committee that is responsible for confirming the validity of the evidence and ensuring the device is safe and effective. Examples of Class III devices include breast implants, vascular sutures, and dermal implant devices.

###### 

FDA Medical Device Classification

  FDA Device Class   Risk            Examples                                 Regulation
  ------------------ --------------- ---------------------------------------- -------------------------------
  Class I            Low risk        Tourniquet sterile dressing              General
  Class II           Moderate risk   Negative pressure wound therapy system   510(k) Premarket notification
  Class III          High risk       Integra -- bilayer wound matrix          PMA approval

The application for plastic surgery devices is reviewed by the General and Plastic Surgery Advisory Committee, a panel responsible for assessing device safety and effectiveness.^[@R3]^ Plastic surgery devices approved by the FDA can be identified by filtering the database for devices indexed as approved by the General and Plastic Surgery Advisory Committee.

After the first device is approved, manufacturers may apply to make postmarket changes. Depending on the modification type, manufacturer's may apply to different premarket approval (PMA) supplement tracks, which include: panel track, 180-day track, real-time, special (immediate) track, 30-day notice, and 135-day track^[@R2]^ (Table [2](#T2){ref-type="table"}). Modifications can range from changing the manufacturing process, device indications, and device design. In the majority of tracks, the clinical data supporting the original device are considered sufficient enough to inform decision making regarding approval of the device modification and new clinical data are often not required.

###### 

FDA Supplement Review Track Pathways

  FDA Supplement Tracks        Panel Track                                                    Special (Immediate) Track             180-day Track                                           Real-time Track           30-day Notice             135-day Supplement
  ---------------------------- -------------------------------------------------------------- ------------------------------------- ------------------------------------------------------- ------------------------- ------------------------- -------------------------
  Primary indication           Labeling change to expand indication, or major design change   Labeling change to improve safety\*   Significant design change\*\*                           Minor design change\*\*   Manufacturing change      Manufacturing change
  Year of track introduction   1990                                                           1986                                  1986                                                    1997                      1997                      1997
  Supporting evidence          Clinical study                                                 Requires no specific new data         Preclinical, confirmatory clinical data in some cases   Preclinical only          No specific requirement   No specific requirement
  Fee in US dollars (2019)     \$241,610                                                      NA                                    \$48,322                                                \$22,550                  \$5,154                   NA
  Reviewer                     Panel of subject matter experts and FDA staff                  FDA staff                             FDA staff                                               FDA staff                 FDA staff                 FDA staff

\*May include process changes.

\*\*May include labeling changes.

Devices that undergo many supplements (ie, modifications) may experience "design drift."^[@R4]^ This phenomenon occurs when a modified medical device is found to be substantially different from the original device. These cumulative changes may significantly transform the original device and undermine previous safety and efficacy testing.

Modification trends remain undescribed in the plastic surgery literature. The primary objective of this study was to highlight the number and quality of device changes over the lifespan of a high-risk plastic surgery device. Secondary objectives included describing the types of Class III plastic surgery devices receiving FDA approval, the types of PMA supplement tracks used, and the number of device recalls and withdrawals. Previous studies in orthopedics,^[@R4]^ dermatology,^[@R5]^ otolaryngology,^[@R6]^ and cardiology^[@R7]^ have identified substantial design changes in high-risk devices approved through the PMA pathway.

METHODS
=======

Search Strategy and Eligibility
-------------------------------

A retrospective, cross-sectional analysis was conducted on all high-risk plastic surgery devices receiving US marketing approval through the FDA PMA pathway by the General and Plastic Surgery Advisory Committee. The publicly accessible PMA database was searched for all original PMAs, device recalls, and device withdrawal records reported through December 31, 2018.

The devices included in this analysis met the following inclusion criteria: devices manufactured primarily for the use by plastic surgeons; devices that are not used commonly in fields outside of plastic surgery; and medical devices included may overlap with other specialties but should reflect plastic surgery specifically as opposed to other areas of medicine. Two authors (O.R.O. and N.S.) screened each approved original PMA device against the inclusion criteria established a priori for eligibility to be included in the analysis. If consensus could not be reached, disagreements were resolved by a third blinded senior reviewer (M.H.M.) to determine final eligibility.

Extraction of Data
------------------

Two authors (O.R.O and D.O) collaborated in the extraction of device data from the PMA database to characterize each original high-risk plastic surgery device and related device supplements. The following data were extracted: initial clearance date, device type, product classification code, implantable status, the number of supplements, type of modification (supplement track), supplement reason, and product withdrawal dates. The product code for each original device was searched in the FDA medical device recall database and the recall information was also extracted. This database was first implemented on November 1, 2002, and contained all recalls issued thereafter.

To best reflect incremental changes in high-risk devices, only labeling, design, and production changes were included in our analysis. FDA applications regarding the change of a manufacturing location or postapproval study design were excluded.

Statistical Analysis
--------------------

The interobserver agreement for the inclusion of plastic surgery devices was calculated using Cohen kappa coefficient. The kappa coefficient was interpreted according to the Landis and Koch (1977) guidelines and was categorized a priori as k = 0.81--1.00 as almost perfect agreement, k = 0.61--0.8 as substantial agreement, k = 0.41--0.6 as moderate agreement, and k = 0.21--0.40 as fair agreement.^[@R8]^ Pearson correlation and Spearman's rank were used to measure the strength and direction of association between different variables.

Descriptive statistics such as median and measures of variance (eg, interquartile range \[IQR\] and SDs, 95% confidence interval \[CI\]) are presented where applicable. Descriptive statistics were used to characterize the median number of devices approved per year and the median number of modifications per year. The number of PMA-approved Class III plastic surgery devices were summed and reported. The number of devices in each category was classified using product codes. The number of original devices and supplement applications approved per year were also calculated and reported. Linear regression was used to determine the change in the original annual PMA approvals and approved supplements over time.

Stata version 12.0 (StataCorp, LP, College Station, TX, USA) was used to perform all statistical analysis. Two-tailed statistical tests were used and a probability of less than 0.05 was considered statistically significant. Google Sheets (Google, California, USA) was utilized for the development of extraction forms and figures.

RESULTS
=======

The FDA has cleared 39 original high-risk plastic surgery devices via the PMA pathway which has served as the basis for a collection of modified devices (Table [3](#T3){ref-type="table"}). The independent duplicate screening demonstrated almost perfect inter-rater agreement with a kappa value of k = 0.86 (95% \[CI\] 0.61--0.90) for device inclusion. The type of devices included breast implants, dermal implants, lasers, sutures, vascular sealants, wound dressings, and an electrical impedance spectrometer.

###### 

Summary of High-risk (Class III) Plastic Surgery Devices

  PMA Number   Manufacturer                           Device                                                                 Approval Year   Product Codes   Type of Device                      No. Supplements   FDA Recall Class (Posting Date)                   Withdrawal Date   Device-years
  ------------ -------------------------------------- ---------------------------------------------------------------------- --------------- --------------- ----------------------------------- ----------------- ------------------------------------------------- ----------------- --------------
  P800022      Allergan                               Zyderm collagen implant(Zyderm CI)                                     1981            LMH             Dermal implant                      35                                                                  10/25/2011        30
  P850053      Mentor Corp.                           Fibrel                                                                 1988            LMH             Dermal implant                      4                                                                   02/28/2008        20
  P870069      UDL Laboratories, Inc.                 Biobrane(R) II                                                         1989            FRO             Wound device                        1                                                                   01/19/2010        21
  P890002      Alcon Laboratories                     Polypropylene Surgical Suture                                          1989            GAW             Suture                              0                                                                                     29
  P900033      Integra LifeSciences Corp.             Integra Dermal Regeneration Template                                   1996            MGR             Wound device                        64                2(2009) 3(2008)                                                     22
  P960007      Shire Regenerative Medicine            Transcyte Human Fibroblast-Derived Temporary Skin Substitute           1997            MGR             Wound device                        12                                                                                    21
  P950032      Organogenesis, Inc.                    Apligraf (Graftskin)                                                   1998            MGR             Wound device                        63                2(2011) 2(2011) 2(2010) 2(2009) 2(2008) 3(2006)                     20
  P990004      Ferrosan Medical Devices A/S           Surgifoam Absorbable Gelatin Sponge, USP                               1999            LMF             Hemostasis adjunct                  0                 1(2012) 1(2012) 2(2012)                                             19
  P990019      Dusa Pharmaceuticals, Inc.             Blu -U Blue Light Photodynamic Therapy Illuminator                     1999            MVF             Laser                               5                                                                                     19
  P990021      Concordia Laboratories, Inc            Diomed 630 PDT Laser                                                   2000            MVF             Laser                               3                                                                                     18
  P990049      Lumenis                                Coherent Opal Photoactivator Laser System                              2000            MVF             Laser                               1                                                                   09/10/2010        10
  P990074      Allergan                               Natrelle Saline Breast Implants                                        2000            FWM             Breast implant                      34                3(2005) 3(2005)                                                     18
  P990075      Mentor Worldwide LLC                   Mentor Corporation Saline-Filled And Spectrum (R) Mammary Prostheses   2000            FWM             Breast implant                      41                2(2017)                                                             18
  P000036      Shire Regenerative Medicine            Dermagraft                                                             2001            MGR             Wound device                        13                2(2003)                                                             17
  P010016      Forticell Bioscience                   Orcel Bilayered Cellular Matrix                                        2001            MGR             Wound device                        2                                                                                     17
  P020023      Q-Med AB                               Restylane Injectable Gel                                               2003            LMH             Dermal implant                      12                                                                                    15
  P060028      Mentor Worldwide LLC                   Mentor Memoryshape Breast Implants                                     2003            FTR             Breast implant                      24                                                                                    15
  P010061      Photo Cure Asa                         Curelight Broadband (Model Curelight 01)                               2004            MYH             Laser                               0                                                                   08/28/2008        4
  P030032      Genzyme Biosurgery                     Hylaform (Hylan B Gel)                                                 2004            LMH             Dermal implant                      12                                                                  02/10/2016        12
  P030050      Q-Med AB                               Sculptra And Sculptra Aesthetic                                        2004            LMH             Dermal implant                      19                                                                                    14
  P040024      Q-Med AB                               Restylane Injectable Gel                                               2005            LMH             Dermal implant                      92                                                                                    13
  P020012      Suneva Medical, Inc.                   Artefill, Bellafill PMMA Collagen Permanent Dermal Filler              2006            LMH             Dermal implant                      15                                                                                    12
  P020056      Allergan                               Natrelle Silicone-Filled Breast Implants                               2006            FTR             Breast implant                      33                                                                                    12
  P030053      Mentor Corp.                           Memorygel Silicone Gel-Filled Breast Implants                          2006            FTR             Breast implant                      31                2(2016)                                                             12
  P050033      Anika Therapeutics, Inc.               Hydrelle                                                               2006            LMH             Dermal implant                      17                                                                                    12
  P050037      Merz North America, Inc                Radiesse 1.3CC And 0.3CC                                               2006            LMH             Dermal implant                      85                2(2011) 3(2011)                                                     12
  P050047      Allergan                               Juvederm 24HV, Juvederm 30 And Juvederm 30HV Gel Implants              2006            LMH             Dermal implant                      61                                                                                    12
  P050052      Merz North America, Inc                Radiesse Injectable Implant                                            2006            LMH             Dermal implant                      93                2(2016) 2(2015) 2(2011) 3(2011)                                     12
  P070013      Colbar Lifescience Ltd.                Evolence Collagen Filler                                               2008            LMH             Dermal implant                      3                                                                   12/03/2010        2
  P060029      Ethicon, Inc.                          Ethicon Omnex Surgical Sealant                                         2010            NBE             Vascular reconstruction adhesive    3                                                                                     8
  P090016      Merz North America, Inc                Belotero Balance                                                       2011            LMH             Dermal implant                      23                                                                                    7
  P070004      Sientra, Inc                           Sientra Silicone Gel Breast Implants                                   2012            FTR             Breast implant                      8                                                                                     6
  P120011      Idealimplant                           Ideal Implant Saline-Filled Breast Implant                             2012            FWM             Breast implant                      12                                                                                    6
  P040046      Allergan                               Natrelle Highly Cohesive Silicone-Filled Breast Implants               2013            FTR             Breast implant                      23                                                                                    5
  P110033      Allergan                               Juvederm Voluma XC                                                     2013            LMH             Dermal implant                      37                                                                                    5
  P140029      Q-Med AB                               Restylane Refyne, Restylane Defyne                                     2016            LMH             Dermal implant                      12                                                                                    2
  P150046      Scibase AB                             Nevisense                                                              2017            ONV             Electrical impedance spectrometer   2                                                                                     1
  P160042      Prollenium Medical Technologies Inc.   Revanesse Ultra                                                        2017            LMH             Dermal implant                      2                                                                                     1
  P170002      Teoxane S.A.                           RHA 2, RHA 3, RHA 4                                                    2017            LMH             Dermal implant                      0                                                                                     1

Pearson's correlation failed to demonstrate a significant association between original high-risk devices release over time (r = 0.28; *P* = 0.084) (Fig. [1](#F1){ref-type="fig"}a). The relationship between PMA supplement usage over time demonstrated an exponential relationship. As such, Spearman's correlation was used to assess the relationship between supplement usage and time (Fig. [1](#F1){ref-type="fig"}b). There was a strong positive correlation between supplement approval over time, which was statistically significant (r~s~ = 0.9174, *P* = 0.000). The FDA cleared 897 total incremental changes for 39 original devices through December 31, 2018 (Table [4](#T4){ref-type="table"}). There were 161 modifications which did not represent device or process changes and were excluded from our analysis (eg, location change or postapproval study protocol change).

###### 

Characteristics of Included Approved High-risk Plastic Surgery Devices

  Devices (n = 39)                     
  ------------------------------------ -------------
  Initial clearance date               n (%)
   1980--1989                          4 (10.0%)
   1990--1999                          5 (13.0%)
   2000--2009                          20 (51.0%)
   2010--present                       10 (26.0%)
  Implantable                          
   Yes                                 26 (67.0%)
   No                                  13 (33.0%)
  Device type                          
   Wound device                        6 (15.0%)
   Breast implant                      8 (20.5%)
   Dermal implant                      17 (43.6%)
   Laser                               4 (10.0%)
   Hemostasis adjunct                  1 (2.50%)
   Vascular reconstruction adhesive    1 (2.5%)
   Electrical impedance spectrometer   1 (2.5%)
   Suture                              1 (2.5%)
   Total                               39
  No. supplements                      
   Breast implant                      206 (23.0%)
   Dermal implant                      522 (58.2%)
   Electrical impedance spectrometer   2 (0.2%)
   Laser                               9 (1.0%)
   Suture                              0 (0.0%)
   Vascular reconstruction adhesive    3 (0.3%)
   Wound device                        155 (17.4%)
   Total                               897

###### 

Total Approved Supplements by Supplement Track

  Supplement Track                     No. Supplements
  ------------------------------------ -----------------
  135 Review track for 30-day notice   108
  30-day notice                        487
  Normal 180-day track                 125
  Not reported                         11
  Panel track                          17
  Real-time process                    102
  Special (immediate track)            47
  Total                                897

![A, Changes in original devices between 1980 and 2018. B, PMA supplements approved between 1980 and 2018.](gox-8-e2621-g001){#F1}

Breast and dermal implants represented 64.1% of the high-risk devices that have come to market via the PMA approval pathway and comprised 81.2% of all modifications to devices which come to market. Radiesse injectable implant underwent the greatest number of changes with 93 supplements since 2006. Of the changes, 57 (62%) were 30-day notice, 6 (6.5%) panel track, 8 (8.7%) special track, 2 (2.2%) real-time track, and 8 (8.7%) normal 180-day track changes. Furthermore, the dermal implant underwent the highest rate of postmarket device changes per device-year, with 7.75 modifications approved per active device-year over a 6-year lifespan. Restylane underwent the second greatest number of changes with 92 modifications since 2005. Dermal medical devices represent 43.6% of the original devices, yet undergo 58% of the device changes, and have a median of 17 changes per device (IQR, 12--38; range, 0--93). Although dermal implants had the greatest number of modifications to an individual device, breast implant devices had the greatest median number of changes. Breast implant devices underwent a median of 27.5 modifications per device (IQR, 20.25--33.25; range, 8--41). Four original devices did not undergo any supplement changes (Table [3](#T3){ref-type="table"}).

Recall and Withdrawal
---------------------

Following initial FDA clearance, 9 (23%) original devices contributed to 22 recalls (Table [3](#T3){ref-type="table"}). There was a moderate positive correlation between the number of supplements and the number of device recalls (r = 0.5413, *P* = 0.0004, R^2^ = 0.239). Only 2 of the recalls were classified as a Class I recall, which is a circumstance where a product is likely to cause serious adverse health consequences or death.^[@R9]^ Apligraf, skin substitute, required the most device recalls with 6 recalls which occurred over 5 years. There were 7 devices withdrawn from the market by manufacturers. FDA databases do not provide a reason for withdrawal.

Types of Postmarket Modifications and Device Lifespan
-----------------------------------------------------

The median lifespan of high-risk therapeutic plastic surgery devices was 12 years (IQR, 6.5--18; range, 1--30 years) (Table [3](#T3){ref-type="table"}). There was an approved total of 620 process changes, 124 design changes, and 64 labeling changes (Table [6](#T6){ref-type="table"}).

###### 

Types of Postmarket Modifications Approved Changes to Devices

  Type of Modification                                                Count
  ------------------------------------------------------------------- -------
  Labeling change -- indications/instructions/shelf life/trade name   139
  Change design/components/specifications/material                    123
  Other report                                                        3
  Process change -- manufacturer/sterilizer/packager/supplier         620
  Special report                                                      1
  Before PMA pathway                                                  11
  Total                                                               897

Refer PMA Database PMA Number (P800022-S035, P950032-S002, P950032-S028) for details.

After the 30-day notice and 135-day track review were formally introduced in 1997, the supplement per active device increased from 0.389 supplements per active device (1990--1999) to 0.630 supplements per active device in the next decade (2000--2009) and to 2.44 supplements per active device from 2010 to 2018.

PMA Supplemental Review Tracks
------------------------------

The use of different types of PMA supplement review tracks has changed over time (Fig. [2](#F2){ref-type="fig"}). The 30-day notice and 135-day review track are the most common type of supplemental review. Approximately 54% (n = 487) of approved supplements were through the 30-day notice track and 12% (n = 108) of the 30-day notice applications result in the FDA requesting for more information via the 135-day review pathway. Real-time review track which requires preclinical data and is intended for minor design changes reviews represented 11% (n = 102) of supplement applications. Special (immediate) track intended for labeling changes meant to enhance device safety represented 5.2% (n = 47) of the supplements. Fourteen percent (n = 125) of supplements were normal 180-day track changes, which are intended for major design changes; 1.9% (n = 17) plastic surgery devices were approved through panel track review, which requires substantial new clinical data and is used to expand use or remove contraindications.

![Variations in PMA supplement utilization over time.](gox-8-e2621-g002){#F2}

Changes by Supplement Review Track
----------------------------------

There was congruence between the published supplement reason and the supplement type (Fig. [3](#F3){ref-type="fig"}). All changes made through the 30-day (n = 487, 100%) and the 135 review track (n = 108, 100%) supplements were related to production changes. Labeling changes is a broad classification by the FDA, which may include changes to indications, instructions, shelf life, and trade name.^[@R10]^

![Types of changes in plastic surgery devices by supplement track.](gox-8-e2621-g003){#F3}

There were 60 (47.8%) labeling modifications which were approved through the 180-day track and 31 (30.4%) labeling modifications through real-time supplement track. Special (immediate) track was used primarily for labeling changes (n = 35, 74.5%) and process changes (n = 12, 25.5%). Panel track review was used to approve 13 labeling changes (76.5%) and 4 design changes (23.5%).

DISCUSSION
==========

This cross-sectional analysis of the FDA PMA database included 39 high-risk therapeutic plastic surgery devices which were approved through the original PMA pathway. These devices were found to undergo a median of 12 changes related to design and labeling over a 12-year median device lifespan. The number of changes a medical device underwent was device specific. Breast and dermal implants composed 81% of all postmarket device modifications but represented 63% of the included plastic surgery devices. Breast implant devices underwent the greatest number of changes with a median of 27.5 changes over a median of 12 active device-years. This may be due to the relatively large commercial market relative to other devices.

The most utilized pathway, 30-day notice, requires no specific additional study or investigation and is primarily used for minor production changes such as switching suppliers for a component.^[@R10]^ Hauser and Maron^[@R11]^ describe a 21-year-old patient who was unknowingly implanted with a defective implantable cardioverter defibrillator and subsequently died. Before the incident, the manufacturer identified the defect and applied for production changes but left the previous iterations on the market. There are other many well-documented cases of medical devices being approved through the PMA pathway, undergoing several approved changes without clinical study and then contributing to preventable harm to patients.^[@R11]^ While such occurrences have not been reported in the plastic surgery literature, it is important to highlight that newer devices not only lack evidence on long-term safety, as this is ascertained in postmarket evaluation, but also undergo several changes with variable amounts of evidence in the premarket stages.

The issues highlighted in this paper remain at the policy level, with the role of surgeons being quite limited. In fact, manufactures are not required to report which supplements apply to a specific model on the packaging and surgeons are often unfamiliar of which specific iteration they are using.^[@R12]^ Nonetheless, the deficiencies of the PMA process highlight the importance of reporting clinical outcomes and adverse events in national registries which enable accurate device assessment in postapproval studies. The high rate of device turnover raises a new challenge of tracking long-term evidence on the safety of devices, especially on rare events.

Previous studies have characterized the types of postmarket device changes in cardiology,^[@R7]^ dermatology,^[@R5]^ otolaryngology,^[@R6]^ and orthopedics.^[@R4]^ High-risk plastic surgery devices undergo lower rates of changes related to design (32.6%) compared to high-risk otolaryngology (52%) and cardiology devices (37%), but more modifications compared to orthopedic devices (22.5%). To the author's knowledge, this is the first study to characterize postmarket modification trends in high-risk plastic surgery devices.

There were a significant number of labeling changes approved through pathways primarily intended for design (Fig. [3](#F3){ref-type="fig"}). Labeling modifications may include changes to indications, instructions, shelf life, and trade name.^[@R10]^ Changes to device indications should be made exclusively through the panel review track, and other labeling changes can be made through 180-day or real-time review supplement tracks.^[@R10]^ Though a formal audit of the approved supplements was beyond the scope of this analysis, the authors identified a 180-day supplement used to expand the indications of a device, which should exclusively undergo panel track review.^[@R10],[@R13]^ Another observation was that real-time and 180-day tracks were used to approve identical design changes in the style and sizes of breast implants.^[@R14],[@R15]^ This was observed across different devices, where similar products may undergo identical changes but require different levels of review before being brought onto the market. The difference between the real-time and 180-day tracks are the depth of review and the amount of evidence used to support the device change.^[@R10]^ While the FDA has the ultimate authority on what devices are approved through each pathway, without consistency, there is a risk for devices being approved via less rigorous pathways. Future studies should assess the congruency between the published supplement track and the approval order statement.

In an effort to promote transparency, the FDA has developed a pilot program releasing select PMA summary review memos for select 180-day design changes and total product life cycle reports, which provide information regarding product clearances, approvals, adverse events, and recalls.^[@R16]^ These initiatives are encouraged as they enhance transparency and should be expanded to include memos on other review tracks. The FDA device user experience database should be indexed by type of incident reported, which may prove useful for research and clinical decision-making purposes.

In plastic surgery, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and other safety concerns have led to profound developments by the FDA in adverse event reporting and device monitoring. In early 2019, the FDA announced the termination of the alternative summary reporting program, a program intended for internal review but concealed reports regarding unusual, unique, or uncommon adverse events, such as breast implant-associated anaplastic large cell lymphoma and breast implant illness.^[@R17]^ Additionally, the FDA has partnered with 2 registries: Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology and National Breast Implant Registry and is taking further steps to enhance the rigour of postapproval studies.^[@R17]^ This is important as these studies will be fundamental in providing long-term safety data. Evidently, there are rapid advancements being made to protect the public and improve the device approval process.

Study Limitations
-----------------

There are several limitations of this study. First, we restricted our analysis to devices published in the PMA database and then selected devices for inclusion. Although reviewers were blinded and agreed with high confidence, there is a risk of selection bias regarding which devices were included and excluded.

Utilizing the PMA database limits our analysis to only high-risk devices approved in the PMA pathway. Evidence suggests that high-risk devices are also inappropriately approved through the less stringent 510(k) pathways.^[@R9]^ Another limitation is that device market withdrawal information is largely dictated by the manufacturer and there is no information regarding the rationale posted on the withdrawal database. Additionally, modifications approved before 1986 remain unclassified. Nonetheless, this is only a small proportion of the included plastic surgery device supplements. Consistent with the nature of any cross-sectional analysis, our study only describes a snapshot in time. The observations made in this analysis were quantitative in nature, and the impact of these modifications on safety and function requires further study.

CONCLUSIONS
===========

Medical devices are essential tools used in the field of plastic surgery, and surgeons should be knowledgeable of how these devices come to market. This analysis of the PMA database included 39 original plastic surgery devices which have underwent a total of 897 modifications. The most frequently used supplements do not require additional clinical testing, which may contribute to substantial design drift in select devices.
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